Please use this identifier to cite or link to this item:
|Title:||Adjuvant letrozole versus tamoxifen according to centrally-assessed ERBB2 status for postmenopausal women with endocrine-responsive early breast cancer: supplementary results from the BIG 1-98 randomised trial|
Altermatt, Hans J
Del Curto, Barbara
Gelber, Richard D. (Prof)
Henriksen, Katrine L
Lykkesfeldt, Anne E
Mastropasqua, Mauro G.
Price, K. N.
Rasmussen, Brigitte B
Regan, Meredith M.
School of Public Health: Public Health
|Publisher:||The Lancet Publishing Group|
|Citation:||Adjuvant letrozole versus tamoxifen according to centrally-assessed ERBB2 status for postmenopausal women with endocrine-responsive early breast cancer: supplementary results from the BIG 1-98 randomised trial, The Lancet, vol.9, N/A, 2008,pp 23-28|
|Department/Unit/Centre:||School of Public Health: Public Health|
|Disclaimer:||This work has been made available to the staff and students of the University of Sydney for the purposes of research and study only. It constitutes material that is held by the University for the purposes of reporting for HERDC and the ERA. This work may not be downloaded, copied and distributed to any third party .|
|Type:||C1 - Refereed Journal articles|
|Appears in Collections:||University of Sydney Research Outputs|
Items in Sydney Research Online are protected by copyright, with all rights reserved, unless otherwise indicated.